^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Onureg (azacitidine oral) (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of oral azacitidine (CC-486) plus R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL: A phase I study
Published date:
09/21/2021
Excerpt:
...Stage II−IV disease, an International Prognostic Index (IPI) score of ≥2 or DLBCL double-positive for BCL2 and MYC…CC-486 was administered daily for 14 days during Cycles 1−5 of R-CHOP…The overall response rate (ORR) was 95%, with 88% of patients attaining complete response (CR) at the 300 mg dose level (Table 2)...Overexpression of BCL2 (≥ 30%) or MYC (≥ 40%) was determined by immunohistochemistry...
